Drug Approval | December 08, 2023
Novartis receives FDA approval for Fabhalta as the first oral monotherapy for adults with PNH
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Multi-ethnic innovation helps all complexions appear clearer and more uniform
The workshop is specially curated for Ayurvedic medical officers from Delhi and Haryana
A new GSK survey shows a large number of adults do not understand how shingles may be triggered
Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution
Decision on EU marketing authorisation expected for momelotinib by early 2024
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Subscribe To Our Newsletter & Stay Updated
